Last updated on August 2019

A Study of Atezolizumab (Anti Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck


Brief description of study

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Clinical Study Identifier: NCT03452137

Find a site near you

Start Over

Southern Cancer Center

Daphne, AL United States
  Connect »

Kaiser Permanente - Bellflower

Bellflower, CA United States
  Connect »

UCLA Hematology/Oncology

Santa Monica, CA United States
  Connect »

Illinois Cancer Care

Peoria, IL United States
  Connect »

Cancer Center of Kansas

Wichita, KS United States
  Connect »

Blue Ridge Cancer Care

Roanoke, VA United States
  Connect »

Adelaide Cancer Centre

Kurralta Park, Australia
  Connect »

City Oncology Hospital; Chemotherapy Dept

Nizhny Novgorod, Russian Federation
  Connect »

Insititut Catala D'Oncologia

Hospitalet de Llobregat, Spain
  Connect »

Queen Elizabeth Hospital

Birmingham, United Kingdom
  Connect »

Velindre Cancer Centre

Cardiff, United Kingdom
  Connect »

ICM; Radiotherapie

Montpellier Cedex 5, France
  Connect »

Kaiser Permanente - Vallejo

Vallejo, CA United States
  Connect »

University of Arizona

Tucson, AZ United States
  Connect »

University of Oklahoma

Los Angeles, CA United States
  Connect »

Georgetown U; Lombardi Comp Can

Washington, WA United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

OSU, James Cancer Hospital

Columbus, OH United States
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

Morristown Medical Center

Morristown, NJ United States
  Connect »